2 September 2023 in Nature Communications
Reprogramming of vascular smooth muscle cell (VSMC) differentiation plays an essential role in abdominal aortic aneurysm (AAA). However, the underlying mechanisms are still unclear. We explore the expression of FAM3A, a newly identified metabolic cytokine, and whether and how FAM3A regulates VSMC differentiation in AAA. We discover that FAM3A is decreased in the aortas and plasma in AAA patients and murine models. Overexpression or supplementation of FAM3A significantly attenuate the AAA formation, manifested by maintenance of the well-differentiated VSMC status and inhibition of VSMC transformation toward macrophage-, chondrocyte-, osteogenic-, mesenchymal-, and fibroblast-like cell subpopulations. Importantly, FAM3A induces KLF4 ubiquitination and reduces its phosphorylation and nuclear localization. Here, we report FAM3A as a VSMC fate-shaping regulator in AAA and reveal the underlying mechanism associated with KLF4 ubiquitination and stability, which may lead to the development of strategies based on FAM3A to restore VSMC homeostasis in AAA.
7 December 2025 in Cell Death & Disease
Obesity-associated insulin resistance (IR) is closely related to intramyocellular lipid accumulation in skeletal muscle. FAM3 metabolism regulating signaling molecule A (FAM3A) is expressed and secreted in almost all tissues. However, its biological roles and underlying mechanisms remain largely unknown. Here, we reported that abnormal lipid metabolism decreased the FAM3A level. To investigate the function of FAM3A, a transgenic mouse strain was generated, in which FAM3A protein was overexpressed systemically. Proteomic analyses revealed that proteins related to lipid metabolic processes, specifically fatty acid (FA) synthesis complex enzymes and adiponectin were upregulated in the skeletal muscles of the FAM3A-transgenic mice compared with those in the skeletal muscles of the wild-type control mice. Furthermore, a positive correlation between FAM3A and adiponectin levels was observed in patient plasma samples. FAM3A transgene or FAM3A injection in high-fat diet (HFD)-fed mice led to increased levels of muscular srebp1, fas, acc, and acly expression, De novo FA biosynthesis, and lipid accumulation compared with those in matched controls. However, FAM3A transgene or FAM3A injection suppressed IR and inflammation and promoted glucose consumption in HFD-fed mice. Moreover, these functions of FAM3A were attenuated by the inhibition of PPARα. Notably, the inhibition of the insulin receptor abolished the linkage of FAM3A and PPARα as well as their downstream metabolic effects. Taken together, these findings suggest that increasing FAM3A expression in the body may represent a unique opportunity to avoid IR in individuals with obesity induced by high lipid levels.
9 June 2026 in Circulation
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, a condition characterized by impaired diastolic function and elevated left ventricular stiffness. TPM1 (tropomyosin 1), a crucial part of the thin filament in cardiomyocytes, has multiple alternative exons. However, the impact of TPM1 alternative splicing (AS) in HFpEF remains unclear. METHODS: We examined cardiac myofiber disarray in HFpEF using transmission electron microscopy. Nanoindentation was used to detect myocardial compliance. Using genetically engineered (adenovirus-associated virus serotype 9) mouse models and human pluripotent stem cell–derived cardiomyocytes, we investigated the role of TPM1 isoforms and its upstream SRPK3 (serine/arginine rich protein kinase 3). Subsequently, the underlying mechanisms were investigated using RNA pulldown, mass spectrometry, AS analysis, and other molecular techniques. RESULTS: We identified unique myofilament disorders in HFpEF and observed upregulation of the TPM1b isoform, which skips exon 9a through AS, in both patients with HFpEF and mouse models. Cardiomyocyte-specific overexpression of distinct TPM1 isoforms showed that TPM1b (without exon 9a) exacerbated HFpEF phenotypes in mice and human pluripotent stem cell–derived cardiomyocytes. Furthermore, we found that the splicing kinase SRPK3 mediates the AS of TPM1 exon 9a. Cardiomyocyte-specific overexpression of SRPK3 induced myofiber disarray and diastolic dysfunction, whereas SRPK3 knockdown ameliorated these pathological phenotypes. Supplementation with TPM1 containing exon 9a partially rescued the diastolic dysfunction under conditions of SRPK3 overexpression. Preventive intervention experiments demonstrated that inactivating SRPK3 can alleviate diastolic dysfunction in the HFpEF mouse model. CONCLUSIONS: AS of TPM1 exon 9a is a critical pathogenic mechanism in myofilament disorder and diastolic dysfunction in HFpEF, which is dependent on the upstream splicing kinase SRPK3. SRPK3 may represent a novel therapeutic target for HFpEF.
20 October 2026 in Cell Death & Disease
The epigenetic mechanisms by which nutrient overload reprograms lymphatic endothelial cells (LECs) remain unclear. Here we show that metabolic stress drives LECs into a glycolytic state, producing lactate that fuels EP300-catalyzed histone H3K18 lactylation at the VEGFR-3 promoter, thereby enhancing chromatin accessibility and VEGFR-3 transcription. This epigenetically induced VEGFR-3 not only promotes LEC proliferation but also engages αVβ1 integrin to activate Src signaling, triggering VE-cadherin internalization and barrier disruption. In mice with metabolic syndrome, this axis drives collecting lymphatic hyperplasia with overt junctional disruption, leading to impaired cardiac lymphatic drainage, myocardial edema, and diastolic dysfunction, a pathological phenotype recapitulated in cardiac lymphatic vessels of metabolic syndrome patients. Genetic ablation of VEGFR-3 in LECs or pharmacological inhibition of lactate production with FX-11 restores lymphatic junctional integrity, improves cardiac drainage, and alleviates myocardial edema. Collectively, these findings establish H3K18 lactylation as a metabolic-epigenetic switch that uncouples lymphatic growth from barrier function under nutrient overload, and identify the LDHA-lactate-H3K18la-VEGFR-3 axis as a targetable node for lymphatic dysfunction in metabolic disease.